LifeWatch One-Lead ECG Patch Receives 510(k) Clearance

Zug, Switzerland -- LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and provider of medical solutions and remote diagnostic monitoring services to the digital health market, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) 510k clearance for its internally-developed LifeWatch Mobile Cardiac Telemetry (MCT) Patch, a 1-lead ECG system.

The LifeWatch MCT 1-Lead Patch is the newest addition to LifeWatch's cardiac diagnostic monitoring offering, and continues to build on LifeWatch's commitment to becoming a truly global provider of remote diagnostic monitoring devices and services.

This latest clearance, when combined with the recently obtained CE mark, enables LifeWatch to provide patients in many parts of the globe with a new diagnostic monitoring patch alternative. The MCT
1-Lead Patch is capable of watching every heartbeat for adverse cardiac events and transmitting significant findings, in near real time, to a clinical service center for immediate follow-up. The MCT 1-Lead Patch technology is an easy to use, discrete and lightweight alternative to traditional recording and transmitting devices. It is significantly more comfortable for the patient and should therefore lead to an increase in the diagnostic yield as a result of improved patient compliance.

Dr. Stephan Rietiker, CEO of LifeWatch, stated: "I am very excited about this milestone which will now allow us to introduce our patch technology to a broader market. The FDA clearance represents yet another significant achievement for LifeWatch and further strengthens our position as an innovational leader in digital health."

About LifeWatch AG: 

LifeWatch AG, headquartered in Zug and listed on SIX Swiss Exchange (LIFE),
Switzerland, is a leading healthcare technology and solution company, specializing in advanced digital health systems and wireless remote diagnostic patient monitoring services. LifeWatch's services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes. LifeWatch AG has operative subsidiaries in the United States, inSwitzerland and in Israel, and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading U.S.-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. 

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, the business strategy, and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.